Investigating a Vaccine Against COVID-19

NCT ID: NCT04400838

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 10811 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-28
• Study Completion Date: 2025-02-05

Brief Summary

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

Detailed Description

There will be 12 study groups and it is anticipated that a total of 12,390 volunteers will be enrolled. Groups 1, 7 & 9 are adults aged 56-69 years; groups 2, 8 & 10 are adults 70 years and over; groups 4, 5 & 6 are adults aged 18-55 years; group 11 is adults aged 18-55 years who have previously received a ChAdOx vectored vaccine; group 12 is HIV positive adults aged 18-55 years.

The vaccine will be administered intramuscularly into the deltoid of the non-dominant arm (preferably).

All subjects will undergo follow-up for a total of 1 year post last vaccination. Additional visits or procedures may be performed at the discretion of the investigators, e.g., further medical history and physical examination, or additional blood tests and other investigations if clinically relevant

Conditions

Coronavirus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Group 1 a1

Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Group 1 a3

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks from prime

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 1 b1

Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost (4-6 weeks apart)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

Group 2 a1

Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Group 2 a3

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 2 b1

.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

Group 4 a1

Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp (Abs 260)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Group 4 b1

Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs 260) prime and 2.2x10\^10vp (qPCR) boost 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

Group 4 c1

Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10\^10vp (Abs260) prime and 2.2x10\^10vp (qPCR) boost\*, at least 4 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 5 a1

Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp, (Abs 260)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Group 5 a3

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10\^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260) boost, minimum 4 weeks from prime

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 5 b1

Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (qPCR)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

Group 5 c1

Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10\^10vp, (qPCR)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (Abs 260)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Group 5 d1

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 5 e1

Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart

Group Type: EXPERIMENTAL

Two dose ChAdOx1 nCoV-19/Covishield 0.5mL

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart

Group 5 f1

Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart

Group Type: EXPERIMENTAL

Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart

Group 6 a1

Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (qPCR)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

Group 6 b1

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)\* boost\* at least 4 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 7 a1

Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (qPCR)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

Group 7 b1

Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 8 a1

Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10\^10vp (qPCR)

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 (qPCR)

Intervention Type: BIOLOGICAL

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

Group 8 b1

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 9 a1

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 10 a1

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 11

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Group 12

Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10\^10 vp, Abs 260)\* 4-6 weeks apart

Group Type: EXPERIMENTAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Single dose MenACWY

Groups 1 a2, 2 a2, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 \& 8 a2 will receive a standard single dose of MenACWY vaccine

Group Type: ACTIVE_COMPARATOR

MenACWY vaccine

Intervention Type: BIOLOGICAL

Standard single dose of MenACWY vaccine

Two dose MenACWY 4 - 6 weeks

Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 \& 10 a2 will receive two doses of MenACWY 4-6 weeks apart

Group Type: ACTIVE_COMPARATOR

Two dose MenACWY vaccine

Intervention Type: BIOLOGICAL

Two standard doses of MenACWY vaccine 4-6 weeks apart

Two dose MenACWY minimum 4 weeks

Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart

Group Type: ACTIVE_COMPARATOR

Two dose MenACWY vaccine min. 4 weeks apart

Intervention Type: BIOLOGICAL

Two standard doses of MenACWY vaccine minimum 4 weeks apart

Interventions

ChAdOx1 nCoV-19 (Abs 260)

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260

Intervention Type: BIOLOGICAL

MenACWY vaccine

Standard single dose of MenACWY vaccine

Intervention Type: BIOLOGICAL

ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later

Intervention Type: BIOLOGICAL

Two dose MenACWY vaccine

Two standard doses of MenACWY vaccine 4-6 weeks apart

Intervention Type: BIOLOGICAL

ChAdOx1 nCoV-19 (qPCR)

A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR

Intervention Type: BIOLOGICAL

ChAdOx1 nCoV-19 0.5mL prime plus boost

Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)

Intervention Type: BIOLOGICAL

Two dose MenACWY vaccine min. 4 weeks apart

Two standard doses of MenACWY vaccine minimum 4 weeks apart

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19/Covishield 0.5mL

Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart

Intervention Type: BIOLOGICAL

Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL

Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart

Intervention Type: BIOLOGICAL

Other Intervention Names

Menveo; Nimenrix; Menveo; Nimenrix; Menveo; Nimenrix

Eligibility Criteria

Inclusion Criteria

• Adults aged 18 - 55 years (groups 4, 5, 6 and 11)
• Adults aged 56-69 years (groups 1, 7, and 9)
• Adults aged 70 years and older (groups 2, 8, and 10)
• Able and willing (in the Investigator's opinion) to comply with all study requirements.
• Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures.
• For females of childbearing potential only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination.
• Agreement to refrain from blood donation during the course of the study.
• Provide written informed consent.

• HIV positive
• Receiving antiretroviral therapy
• Undetectable HIV viral load
• CD4>350 cells/mL

Exclusion Criteria

• Participation in COVID-19 prophylactic drug trials for the duration of the study.

Note: Participation in COVID-19 treatment trials is allowed in the event of hospitalisation due to COVID-19. The COV002 study team should be informed as soon as possible.

• Participation in SARS-CoV-2 serological surveys where participants are informed of their serostatus for the duration of the study.

Note: Disclosure of serostatus post enrolment may accidently unblind participants to group allocation. Participation in COV002 can only be allowed if volunteers are kept blinded to their serology results from local/national serological surveys

• Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination, with the exception of the licensed seasonal influenza vaccination and the licensed pneumococcal vaccination. Participants will be encouraged to receive these vaccinations at least 7 days before or after their study vaccine.
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
• Any confirmed or suspected immunosuppressive or immunodeficient state (except group 12, where HIV infected participants are allowed); asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days)
• History of allergic disease or reactions likely to be exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY
• Any history of angioedema.
• Any history of anaphylaxis.
• Pregnancy, lactation or willingness/intention to become pregnant during the study.
• Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
• History of serious psychiatric condition likely to affect participation in the study.
• Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
• Continuous use of anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
• Suspected or known current alcohol or drug dependency.
• Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
• Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)
• History of laboratory confirmed COVID-19 (except groups 5d, 5e, 5f, 9, 10 and 11).
• Seropositivity to SARS-CoV-2 before enrolment (except groups 5d, 5e, 5f, 9, 10 and 11)
• NB: volunteers with previous NAAT positive results are also allowed in groups 9, 10 and 11

• History of allergic disease or reactions likely to be exacerbated by Paracetamol
• Note: Caution should be taken when recommending paracetamol to adults who already take paracetamol chronically

• Anaphylactic reaction following administration of vaccine
• Pregnancy. An exception to this will be prior to receipt of a booster dose at extra visit B. If a pregnant woman has discussed vaccination with their usual clinician (e.g. GP) and chooses to receive a COVID-19 vaccination, this may be administered by the trial team as part of extra visit B. (Protocol 19.0) or as part of the provision of treatment to controls.
• Any AE that in the opinion of the Investigator may affect the safety of the participant or the interpretation of the study results

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew Pollard, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Locations

University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, United Kingdom

Castle Hill Hospital

Cottingham, Hull, United Kingdom

St Georges University Hospital NHS Foundation Trust

London, Tooting, United Kingdom

University Hospitals Birmingham NHS Foundation Trust

Birmingham, , United Kingdom

University Hospitals Bristol and Weston NHS Foundation Trust

Bristol, , United Kingdom

North Bristol NHS Trust

Bristol, , United Kingdom

NIHR Cambridge Clinical Research Facility

Cambridge, , United Kingdom

NHS Lothian, Western General Hospital

Edinburgh, , United Kingdom

Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital

Glasgow, , United Kingdom

Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator

Liverpool, , United Kingdom

London North West University Healthcare Trust (LNWUH), Northwick Park Hospital

London, , United Kingdom

University College London Hospitals NHS Foundation Trust

London, , United Kingdom

Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital

London, , United Kingdom

Imperial College Healthcare NHS Trust

London, , United Kingdom

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary

Newcastle upon Tyne, , United Kingdom

Public Health Wales

Newport, , United Kingdom

University of Nottingham Health Service, Cripps Health Centre, University Park

Nottingham, , United Kingdom

CCVTM, University of Oxford, Churchill Hospital

Oxford, , United Kingdom

John Radcliffe Hospital

Oxford, , United Kingdom

Sheffield Teaching Hospitals, Royal Hallamshire Hospital

Sheffield, , United Kingdom

Countries

United Kingdom

References

Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, Aley PK, Ansari MA, Bara A, Broadhead S, Brown A, Brown H, Cappuccini F, Cinardo P, Dejnirattisai W, Ewer KJ, Fok H, Folegatti PM, Fowler J, Godfrey L, Goodman AL, Jackson B, Jenkin D, Jones M, Longet S, Makinson RA, Marchevsky NG, Mathew M, Mazzella A, Mujadidi YF, Parolini L, Petersen C, Plested E, Pollock KM, Rajeswaran T, Ramasamy MN, Rhead S, Robinson H, Robinson N, Sanders H, Serrano S, Tipton T, Waters A, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Screaton GR, Winston A, Hill AV, Gilbert SC, Carroll M, Pollard AJ, Fidler S, Fox J, Lambe T, Frater J. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight. 2022 Apr 8;7(7):e157031. doi: 10.1172/jci.insight.157031.

Reference Type: DERIVED

PMID: 35192543 (View on PubMed)

Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T; Oxford COVID Vaccine Trial group. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021 Sep 11;398(10304):981-990. doi: 10.1016/S0140-6736(21)01699-8. Epub 2021 Sep 1.

Reference Type: DERIVED

PMID: 34480858 (View on PubMed)

Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA, Bara A, Bittaye M, Broadhead S, Brown A, Brown H, Cappuccini F, Cooney E, Dejnirattisai W, Dold C, Fairhead C, Fok H, Folegatti PM, Fowler J, Gibbs C, Goodman AL, Jenkin D, Jones M, Makinson R, Marchevsky NG, Mujadidi YF, Nguyen H, Parolini L, Petersen C, Plested E, Pollock KM, Ramasamy MN, Rhead S, Robinson H, Robinson N, Rongkard P, Ryan F, Serrano S, Tipoe T, Voysey M, Waters A, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Screaton GR, Winston A, Hill AVS, Gilbert SC, Pollard AJ, Fidler S, Fox J, Lambe T; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 Aug;8(8):e474-e485. doi: 10.1016/S2352-3018(21)00103-X. Epub 2021 Jun 18.

Reference Type: DERIVED

PMID: 34153264 (View on PubMed)

Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T, Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard AJ; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0. Epub 2021 Mar 30.

Reference Type: DERIVED

PMID: 33798499 (View on PubMed)

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.

Reference Type: DERIVED

PMID: 33617777 (View on PubMed)

Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman A, Wright D, Bellamy D, Bittaye M, Dold C, Provine NM, Aboagye J, Fowler J, Silk SE, Alderson J, Aley PK, Angus B, Berrie E, Bibi S, Cicconi P, Clutterbuck EA, Chelysheva I, Folegatti PM, Fuskova M, Green CM, Jenkin D, Kerridge S, Lawrie A, Minassian AM, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy MN, Robinson H, Song R, Snape MD, Tarrant R, Voysey M, Watson MEE, Douglas AD, Hill AVS, Gilbert SC, Pollard AJ, Lambe T; Oxford COVID Vaccine Trial Group. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.

Reference Type: DERIVED

PMID: 33335323 (View on PubMed)

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.

Reference Type: DERIVED

PMID: 33306989 (View on PubMed)

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.

Reference Type: DERIVED

PMID: 33220855 (View on PubMed)

Other Identifiers

COV002

Identifier Type: -

Identifier Source: org_study_id